All In Biotech

Drug Trial Radar · NCT06614621

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

A Single-arm, Single-center, Prospective Clinical Study of Adebelimab Combined With Chemotherapy for First-line Treatment of Sequential Adebelimab Plus Apatinib Maintenance Therapy in Patients With Extensive-stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Fujian Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer

Conditions

  • Extensive-Stage Small Cell Lung Cancer

Interventions

  • Adebrelimab +Etoposide+Platinum-based drugsDrug

    Adebrelimab:20mg/kg或1200mg ivgtt ,d1 ,Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs:75mg/m2, ivgtt, d1,d2,d3,Q3W

  • Maintenance treatment period:Drug

    Adebrelimab:20mg/kg或1200mg,IV, Q3W; Apatinib Mesylate Tablets:250mg,P.O,qod

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival(PFS)Time frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.